Journal
MOLECULAR PHARMACEUTICS
Volume 13, Issue 6, Pages 1843-1854Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.6b00004
Keywords
nanoparticles; drug delivery; brain metastatic breast cancer; chemotherapeutics; metastatic microsatellites
Funding
- National Institute of Neurological Disorders and Stroke [R01NS077388]
- High Level Talent Research Start-Up Funding of Tongji University [142178]
- Shanghai Pujiang Talent Program [15PJ1407800]
- Howard Hughes Medical Institute through the HHMI Medical Research Fellows Program
- ABTA Research Fellowship - Bradley Benton Davis Memorial Foundation
Ask authors/readers for more resources
As therapies continue to increase the lifespan of patients with breast cancer, the incidence of brain metastases has steadily increased, affecting a significant number of patients with metastatic disease. However, a major barrier toward treating these lesions is the inability of therapeutics to penetrate into the central nervous system and accumulate within intracranial tumor sites. In this study, we designed a cell-penetrating gold nanoparticle platform to increase drug delivery to brain metastatic breast cancer cells. TAT peptide modified gold nanoparticles carrying doxorubicin led to improved cytotoxicity toward two brain metastatic breast cancer cell lines with a decrease in the IC50 of at least 80% compared to free drug. Intravenous administration of these particles led to extensive accumulation of particles throughout diffuse intracranial metastatic microsatellites with cleaved caspase-3 activity corresponding to tumor foci. Furthermore, intratumoral administration of these particles improved survival in an intracranial MDA-MB-231-Br xenograft mouse model. Our results demonstrate the promising application of gold nanoparticles for improving drug delivery in the context of brain metastatic breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available